When was Avere Therapeutics founded?

Avere Therapeutics was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is Avere Therapeutics located?

Avere Therapeutics is headquartered in Sacramento, United States.

Is Avere Therapeutics a funded company?

Avere Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series D round on Aug 10, 2026.

When was the latest funding round of Avere Therapeutics?

Avere Therapeutics' latest funding was a $***** Series D round on Aug 10, 2026, with participation from 9 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.02B in funding in 2026 to date.

Where does Avere Therapeutics rank among its competitors?

Avere Therapeutics ranks 154th amongst 309 active competitors, of which 122 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Avere Therapeutics?

Avere Therapeutics' top competitors include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Avere Therapeutics - 2026 Company Profile, Funding & Competitors

Avere Therapeutics is a series D company based in Sacramento (United States), founded in 2026. It operates as a Developer of oral interleukin twenty-three receptor antagonist drug delivery treatments. Avere Therapeutics has raised $500M in funding. The company has 309 active competitors, including 122 funded and 69 that have exited. Its top competitors include companies like Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics.

Company Details

Developer of oral interleukin twenty-three receptor antagonist drug delivery treatments. This pharmaceutical candidate aims to treat chronic inflammatory conditions by targeting the interleukin receptor pathway. The research focuses on drug engineering to improve exposure and plasma half-life through oral administration. Application of this medication is intended for autoimmune disorders including plaque psoriasis, ulcerative colitis, Crohn disease, and psoriatic arthritis.

Website: averetx.com
Email ID: *****@averetx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2026

Location

Sacramento, United States

Stage

Series D

Total Funding

$500M in 1 round

Latest Funding Round

Series D, Aug 10, 2026, $*****

Investors

RTW Investments & 8 more

Ranked

154^th among 309 active competitors

Similar Companies

Sana Biotechnology & 336 more

View Avere Therapeutics' full profile

Avere Therapeutics has raised a total funding of $500M over 1 round. Its latest funding round was a Series D round on Aug 10, 2026 for $*****. 9 investors participated in its latest round. Avere Therapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Avere Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 10, 2026	6145022	Series D	7667497	9066428	2926502	7508594

Access funding benchmarks and valuations. Sign up today!

View details of Avere Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avere Therapeutics include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Here is the list of Top 10 competitors of Avere Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
3rd	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
4th	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, Nextech Invest & 7 others	65/100
5th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
6th	Sonoma Biotherapeutics 2012, San Francisco (United States), Series B	Developer of T-cell-based therapies for autoimmune and degenerative diseases	$335M	Lilly Asia Ventures, Octagon Capital Advisors ... & 20 others	64/100
7th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	64/100
8th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	VenBio, Redmile Group & 10 others	64/100
9th	Alumis 2003, San Francisco (United States), Public	Developer of therapeutics for the treatment of auto-immune disease	$529M	Foresite Capital, VenBio & 15 others	63/100
10th	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 7 others	63/100
154th	Avere Therapeutics 2026, Sacramento (United States), Series D	Developer of oral interleukin twenty-three receptor antagonist drug delivery treatments	$500M	RTW Investments, BB Biotech & 7 others	35/100